Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yardena Samuels

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
Cell Cycle (Georgetown, Tex.)|October 7, 2004
Oncogenic mutations of PIK3CA in human cancersYardena Samuels, Victor E Velculescu
Cancer Biology & Therapy|May 24, 2005
Inhibiting phosphoinositide 3-kinasesYardena Samuels, Jiuxiang Zhu, Christoph Lengauer
Nature Genetics|February 26, 2015
YAP and the drug resistance highwayAlona Keren-Paz, Rafi Emmanuel, Yardena Samuels
Human Mutation|December 28, 2016
Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and PublicationsThierry Soussi, Peter E M Taschner, Yardena Samuels
Oncogene|March 23, 2005
Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradationDaniele Bergamaschi, Yardena Samuels, Shan Zhong, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 8, 2017
Genetic and Functional Analysis of GRIN2A in Tumor SamplesTodd D Prickett, Jared J Gartner, Yardena Samuels
Cell Cycle (Georgetown, Tex.)|October 22, 2009
Protective roles of matrix metalloproteinases: from mouse models to human cancerCarlos López-Otín, Lavanya H Palavalli, Yardena Samuels
Cancer Research|March 28, 2019
Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma CellsOr-Yam Revach, Oded Sandler, Yardena Samuels, et al.
Nature Reviews. Cancer|February 2, 2022
Mechanisms of immune activation and regulation: lessons from melanomaShelly Kalaora, Adi Nagler, Jennifer A Wargo, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
ERBB4 mutation analysis: emerging molecular target for melanoma treatmentChristopher Lau, Keith J Killian, Yardena Samuels, et al.
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
Cell Cycle (Georgetown, Tex.)|October 7, 2004
Oncogenic mutations of PIK3CA in human cancersYardena Samuels, Victor E Velculescu
Cancer Biology & Therapy|May 24, 2005
Inhibiting phosphoinositide 3-kinasesYardena Samuels, Jiuxiang Zhu, Christoph Lengauer
Nature Genetics|February 26, 2015
YAP and the drug resistance highwayAlona Keren-Paz, Rafi Emmanuel, Yardena Samuels
Human Mutation|December 28, 2016
Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and PublicationsThierry Soussi, Peter E M Taschner, Yardena Samuels
Oncogene|March 23, 2005
Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradationDaniele Bergamaschi, Yardena Samuels, Shan Zhong, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 8, 2017
Genetic and Functional Analysis of GRIN2A in Tumor SamplesTodd D Prickett, Jared J Gartner, Yardena Samuels
Cell Cycle (Georgetown, Tex.)|October 22, 2009
Protective roles of matrix metalloproteinases: from mouse models to human cancerCarlos López-Otín, Lavanya H Palavalli, Yardena Samuels
Cancer Research|March 28, 2019
Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma CellsOr-Yam Revach, Oded Sandler, Yardena Samuels, et al.
Nature Reviews. Cancer|February 2, 2022
Mechanisms of immune activation and regulation: lessons from melanomaShelly Kalaora, Adi Nagler, Jennifer A Wargo, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
ERBB4 mutation analysis: emerging molecular target for melanoma treatmentChristopher Lau, Keith J Killian, Yardena Samuels, et al.
Pageof 11